Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic modulator (EMM) compositions. The company’s product candidates are comprised of EMMs and derivatives that are engineered in distinct combinations and ratios to reset multiple biological pathways, improve cellular energetics, and restore homeostasis. Axcella’s pipeline includes lead therapeutic candidates in Phase 2 development for the reduction in risk of overt hepatic encephalopathy (OHE) recurrence, the treatment of Long COVID, and the treatment of non-alcoholic steatohepatitis (NASH). The company’s unique model allows for the evaluation of its EMM compositions through non-IND clinical studies or IND clinical trials. For more information, please visit www.axcellatx.com.
Company Details
- Employees
- 14
- Founded
- -
- Address
- 840 Memorial Drive, Cambridge,ma 02139,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.axcellatx.com
- HQ
- Cambridge, MA
Axcella Questions
Axcella's website is http://www.axcellatx.com
Axcella's LinkedIn profile is https://www.linkedin.com/company/axcella-tx
Axcella has
14 employees.
View email and phone details for 14
employees at Axcella.
Axcella's industry is
Biotechnology Research
Axcella's top competitors are
Dicerna Pharmaceuticals, Inc.,
Novartis,
Alnylam Pharmaceuticals,
Seres Therapeutics,
Valo Health,
Sana Biotechnology, Inc.,
Flagship Pioneering,
Apellis Pharmaceuticals,
Kaleido Biosciences,
Fore Biotherapeutics.
Axcella's categories are Biotechnology Research
Axcella's founding year is 2010
